Which statement best describes the liver effect on drug bioavailability?

Which statement best describes the liver effect on drug bioavailability?

• A. No effect on drug bioavailability
• B. HPFE and metabolism modifications of drugs
• C. Increased excretion of drugs
• D. Renal clearance unaffected

Answer: (B)

The liver primarily lowers the amount of drug that reaches the bloodstream after oral dosing through the hepatic first-pass effect and metabolic modification. As drugs pass through the liver, they are metabolized by enzymes (like those in cytochrome P450 systems). This can dramatically reduce the active drug’s concentration in systemic circulation, and it can also create active or inactive metabolites. That’s why the best description is that the liver causes first-pass metabolism and metabolic changes of drugs, which directly affects bioavailability. The other statements miss this key mechanism; bioavailability isn’t simply “no effect,” and while hepatic metabolism can influence later excretion, the defining impact on bioavailability is the first-pass metabolism in the liver.

The liver primarily lowers the amount of drug that reaches the bloodstream after oral dosing through the hepatic first-pass effect and metabolic modification. As drugs pass through the liver, they are metabolized by enzymes (like those in cytochrome P450 systems). This can dramatically reduce the active drug’s concentration in systemic circulation, and it can also create active or inactive metabolites. That’s why the best description is that the liver causes first-pass metabolism and metabolic changes of drugs, which directly affects bioavailability. The other statements miss this key mechanism; bioavailability isn’t simply “no effect,” and while hepatic metabolism can influence later excretion, the defining impact on bioavailability is the first-pass metabolism in the liver.